Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines

Simple item page
dc.contributor.authorSchilling, Andrea
dc.contributor.authorMacias Parra, Mercedes
dc.contributor.authorGutierrez, Maricruz
dc.contributor.authorRestrepo, Jaime
dc.contributor.authorUcros, Santiago
dc.contributor.authorHerrera, Teobaldo
dc.contributor.authorEngel, Eli
dc.contributor.authorHuicho, Luis
dc.contributor.authorShew, Marcia
dc.contributor.authorMaansson, Roger
dc.contributor.authorCaldwell, Nicole
dc.contributor.authorLuxembourg, Alain
dc.contributor.authorSobanjo ter Meulen, Ajoke
dc.date.accessioned2017-05-03T20:00:02Z
dc.date.available2017-05-03T20:00:02Z
dc.date.issued2001
dc.description.abstractBACKGROUND: This study in 11- to 15-year-old boys and girls compared the immunogenicity and abstract safety of GARDASIL 9 (9-valent human papillomavirus [9vHPV] vaccine) administered either concomitantly or nonconcomitantly with 2 vaccines routinely administered in this age group (Menactra [MCV4; Neisseria meningitidis serotypes A/C/Y/W-135] or Adacel [Tdap; diphtheria/tetanus/acellular pertussis]). METHODS: Participants received 9vHPV vaccine at day 1 and months 2 and 6; the concomitant group (n = 621) received MCV4/Tdap concomitantly with 9vHPV vaccine at day 1; the nonconcomitant group (n = 620) received MCV4/Tdap at month 1. Antibodies to HPV-, MCV4-, and Tdap-relevant antigens were determined. Injection-site and systemic adverse events (AEs) were monitored for 15 days after any vaccination; serious AEs were monitored throughout the study. RESULTS: The geometric mean titers for all HPV types in 9vHPV vaccine 4 weeks after dose 3, proportion of subjects with a fourfold rise or greater in titers for 4 N meningitidis serotypes 4 weeks after injection with MCV4, proportion of subjects with antibody titers to diphtheria and tetanus $0.1 IU/mL, and geometric mean titers for pertussis antigens 4 weeks after injection with Tdap were all noninferior in the concomitant group compared with the nonconcomitant group. Injection-site swelling occurred more frequently in the concomitant group. There were no vaccine-related serious AEs. CONCLUSIONS: Concomitant administration of 9vHPV vaccine with MCV4/Tdap was generally well tolerated and did not interfere with the antibody response to any of these vaccines. This strategy would minimize the number of visits required to deliver each vaccine individually.
dc.format.extent12
dc.identifier.citationPediatrics September 2015, VOLUME 136 / ISSUE 3
dc.identifier.urihttp://hdl.handle.net/11447/1187
dc.identifier.urihttp://dx.doi.org/10.1542/peds.2014-4199
dc.language.isoen_US
dc.publisherElsevier
dc.subjectInfectious Disease
dc.subjectSexually Transmitted Infections
dc.subjectVaccine/Immunization
dc.titleCoadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines
dc.typeArtículo

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines___resumen.pdf
Size:
261.97 KB
Format:
Adobe Portable Document Format
Description:
Resumen
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services